Actividad in vitro de moxifloxacino frente a patógenos respiratorios en iberoamérica

H. López, H. Sader, C. Amábile, W. Pedreira, J. L. Muñoz Bellido, J. A. García Rodríguez, P. García, V. Prado, J. Robledo, O. Sussmann, Y. Blandon, P. Díaz, G. Ponce, F. Quiñones, R. Fagundo, D. Akle, G. Barriga, A. Guillén, R. Zerpa, J. L. BauerM. Comegna, B. Gallegos

    Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

    4 Citas (Scopus)

    Resumen

    We compared the in vitro activity of moxifloxacin, levofloxacin and six other antibiotics frequently used in respiratory tract infections, against 1563 Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis clinical isolates from 21 centers in 10 Latin American countries from March 2000 to April 2001. Moxifloxacin was the most active compound against all the species included. Moxifloxacin was 2- to 4-fold more active than levofloxacin against Gram-positive bacteria. This difference was much higher against levofloxacin-resistant S. pneumoniae isolates (MIC. 0.5 mg/l vs 8 mg/l). The activity of moxifloxacin against H. influenzae and M. catarrhalis was similar to levofloxacin; all the isolates were inhibited at ≤1 mg/l concentrations of moxifloxacin and levofloxacin.

    Título traducido de la contribuciónIn vitro activity of moxifloxacin against respiratory pathogens in Latin America
    Idioma originalEspañol
    Páginas (desde-hasta)325-334
    Número de páginas10
    PublicaciónRevista Espanola de Quimioterapia
    Volumen15
    N.º4
    EstadoPublicada - dic. 2002

    Palabras clave

    • Fluoroquinolones
    • Latin American
    • Moxifloxacin
    • Respiratory tract infection

    Huella

    Profundice en los temas de investigación de 'Actividad in vitro de moxifloxacino frente a patógenos respiratorios en iberoamérica'. En conjunto forman una huella única.

    Citar esto